Loading
HKSEHealthcareMedical - Diagnostics & Research
Latest quote
HK$72.80
−HK$0.30 · -0.41%
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Latest quote
HK$72.80
−HK$0.30 · -0.41%
Regular session · HKT · Market data may be delayed.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Day range
Current HK$72.80
52-week range
Current HK$72.80
Regular session · HKT · Market data may be delayed.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Day range
Current HK$72.80
52-week range
Current HK$72.80
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.94B CNY | 4.05B CNY | 2.12B CNY | 990.42M CNY | 311.13M CNY |
| Cost of goods sold | 3.8B CNY | 2.81B CNY | 1.56B CNY | 729.34M CNY | 197.64M CNY |
| Gross profit | 2.14B CNY | 1.24B CNY | 559.56M CNY | 261.08M CNY | 113.49M CNY |
| Research and development | 147.21M CNY | 99.96M CNY | 76.87M CNY | 33.84M CNY | 13.82M CNY |
| Selling, general, and administrative | 334.57M CNY | 220.32M CNY | 139.19M CNY | 57.98M CNY | 29.89M CNY |
| Operating expenses | 518.63M CNY | 291.31M CNY | 194.06M CNY | 135.19M CNY | 42.8M CNY |
| Interest income | 183.82M CNY | 185.19M CNY | 47.36M CNY | 4.61M CNY | 28K CNY |
| Interest expense | 16.97M CNY | 3.21M CNY | 742K CNY | 2.92M CNY | 493K CNY |
| Depreciation and amortization | 145.42M CNY | 110.39M CNY | 54.78M CNY | 25.85M CNY | 18.14M CNY |
| Operating income | 1.62B CNY | 948.54M CNY | 365.5M CNY | 125.89M CNY | 60.13M CNY |
| Net income | 1.48B CNY | 1.07B CNY | 283.54M CNY | 155.73M CNY | 54.93M CNY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS37.52M0.01%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO36.19M0.02%162.3B USD0.06%$61.44+0.74%
iShares MSCI Emerging Markets ETFEEM8.62M0.03%31.22B USD0.72%$68.70+1.82%
iShares MSCI China ETFMCHI8.6M0.14%6.28B USD0.59%$54.91+0.99%
Vanguard FTSE All-World ex-US ETFVEU6M0.01%95.9B USD0.04%$86.41+0.54%
iShares Core MSCI Total International Stock ETFIXUS5.39M0.01%60.45B USD0.07%$98.71+0.57%
Schwab Emerging Markets Equity ETFSCHE4.38M0.03%12.94B USD0.06%$37.58+0.75%
Dimensional - Emerging Core Equity Market ETFDFAE2.76M0.03%10.03B USD0.29%$40.57+1.45%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares MSCI Emerging Markets ETFEEMiShares MSCI China ETFMCHIVanguard FTSE All-World ex-US ETFVEUiShares Core MSCI Total International Stock ETFIXUSSchwab Emerging Markets Equity ETFSCHEDimensional - Emerging Core Equity Market ETFDFAEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
